Bioviiix

is a biotech & pharmaceutical company operating in the field of hemocoagulopathies and rare diseases, with particular specialization in the hemophilia segment. Thanks to the expertise of our management and all our resources, we are able to carry forward a model that combines scientific research with a market approach that stands out for the enormous consideration we reserve for ethical principles and respect. Furthermore, in order to introduce innovative methodologies and tools that improve patient support and with a view to upgrading internal and external business flows, we have chosen to start scientific research initiatives in collaboration with universities, organizations and specialized national and international centers. A process that starts from the identification of the financing initiatives that are functional to the development of the activity and the best resources available for the success of the same. For these purposes, the group is part of today- AnBition Start Up controlled by in collaboration with CNR -IGB - Naples, Italy Startup based in Naples, deals with innovative biotechnological research in the Antitumor field more specifically the projects on which is focused on the inhibition of angiogenesis, the newborn Start Up has filed international patents in this regard and is strongly committed to the development of new pharmaceutical forms and new routes of administration of the developed therapies- 3P Sense LTD - London Startup based in London, deals with innovative biotechnological research and in 2016 obtained the patent "Cantilever sensors for molecule detection"- Oncovix Startup specialized in cancer research, in 2017 obtained the patent for a new cancer drug "Duo Fix Combination" for pancreatic